Bem-estar íntimo e ginecologia regenerativa em Dublin | EC Clinic

What does the free HRT arrangement actually cover in Ireland?

It covers the cost of the HRT medication itself and the pharmacy dispensing fee, at the point of dispensing, in pharmacies participating in the arrangement. At EC Clinic in Dublin, tratamento da menopausa starts with assessment and a plan, not only a prescription.

The arrangement launched on 1 June 2025. It was funded through Budget 2025, with the Department of Health announcing a twenty million euro full-year investment, and it is underpinned by the Health Insurance (Amendment) and Health (Provision of Menopause Products) Act 2024 together with subsequent commencement and secondary legislation. It applies to HRT products prescribed for the treatment of symptoms associated with all stages of menopause, where HRT has been determined clinically appropriate and prescribed by your healthcare provider.

Practically, that means a woman who previously paid a prescription charge or a dispensing fee for her HRT now pays nothing for the covered products at a participating pharmacy. The HSE operates a pharmacy finder so you can identify which pharmacies near you have signed up.

It is a meaningful change. Cost was a real barrier, particularly for women managing symptoms over years rather than months, and removing it has brought a great many women into treatment who had been managing alone.

Who is eligible, and what do I need at the pharmacy?

Three things, and the third is the one people trip over.

• A valid prescription for HRT from your healthcare provider.
• Either a medical card, or registration with the HSE Drugs Payment Scheme.
• Your Drugs Payment Scheme number, if you do not have a medical card. This is normally your PPS number with an additional letter, and you can register at mydps.ie.

The Drugs Payment Scheme is open to anyone ordinarily resident in Ireland, which means living here and intending to stay for at least a year. There is no means test. If you have recently moved to Ireland and have never had reason to register, this is the step that most often delays access, and it is straightforward to complete online. Further detail is on the HSE Drugs Payment Scheme page and on Citizens Information.

I mention this specifically because a large proportion of my patients were not born here. Nobody hands you a manual on how the Irish health system works when you arrive. Explaining eligibility, entitlements and the practical route to a pharmacy is part of what a consultation with me includes, in English, Spanish or Portuguese.

Free medication is not the same as the right plan. Why does that matter?

Because HRT is not one thing. It is a category containing different hormones, different doses and different routes of delivery, and the combination has to be matched to the individual woman.

Oestrogen can be given as a tablet, a patch, a gel or a spray. The route is a clinical decision, not a preference: absorption through the skin avoids first-pass metabolism in the liver, which is relevant for some women and not for others. If you have a uterus, oestrogen must be combined with a progestogen to protect the lining of the womb, and the choice and schedule of that progestogen affect both safety and how you feel. Some women additionally benefit from a discussion about testosterone, which is used in specific circumstances.

Then there is titration. The starting dose is a starting point, not a verdict. Symptoms are reassessed, doses are adjusted, and the plan evolves. Menopause care is a relationship over time, not a single transaction at a pharmacy counter.

And there are the women for whom systemic HRT is not appropriate, or who choose not to take it. They still deserve a plan. Non-hormonal options exist for vasomotor symptoms, local treatment can be used for intimate symptoms, and lifestyle foundations, particularly resistance exercise, sleep, alcohol and bone health, are not consolation prizes. They are part of the medicine.

What is genitourinary syndrome of menopause?

It is the recognised medical term for the changes that occur in the vulval, vaginal and lower urinary tract tissues when oestrogen falls, and it replaced the older and narrower term vaginal atrophy because the condition involves more than the vagina.

Oestrogen maintains the thickness of the vaginal lining, its elasticity, its blood supply, its natural lubrication and the acidic environment that supports protective lactobacilli. When oestrogen declines, the tissue becomes thinner and drier, less elastic and more fragile, and the pH rises.

The symptoms follow logically from that biology: dryness, burning or itching, discomfort or pain during sex, a feeling of tightness, spotting after intercourse because fragile tissue bleeds more easily, urinary urgency and frequency, and recurrent urinary tract infections. Estimates of prevalence vary by definition and population, but vaginal symptoms are commonly reported in the region of forty to sixty per cent of postmenopausal women, and many studies suggest under-reporting rather than over-reporting.

The single most important clinical fact about it is this. Unlike hot flushes, which usually improve with time, genitourinary syndrome of menopause is progressive. It does not resolve on its own. Waiting does not help, and the tissue changes are easier to address earlier than later.

Why is vaginal oestrogen so underused?

Partly because nobody asks, partly because women have been taught not to raise it, and partly because of a fear about hormones that does not apply to this particular treatment.

Vaginal oestrogen is applied locally as a cream, pessary or ring. It acts on the tissue where it is applied, and systemic absorption is minimal at the doses used. That is a fundamentally different pharmacological situation from systemic HRT, and the risk profile is correspondingly different. It restores tissue thickness, elasticity, lubrication and the healthy acidic environment, and it reduces recurrent urinary tract infections in postmenopausal women, which is a benefit many women do not know exists.

It can be used alongside systemic HRT. This surprises people. A woman can be on patches for hot flushes and still have intimate dryness, because systemic doses do not always fully resolve local symptoms, and adding local treatment is common and appropriate.

Vaginal creams and pessaries are among the types of HRT recognised under the Irish scheme, alongside tablets, patches, gels and sprays. So for many women this is not only effective, it is now also covered. Very few of my patients arrive knowing that.

Results take time. Improvement is usually noticeable within a few weeks, with fuller benefit over about three months, and it needs to be continued, because stopping allows the tissue to revert. Alongside it, a regular vaginal moisturiser used routinely, not only before sex, and a good lubricant for intercourse both add real comfort. Moisturiser and oestrogen are not alternatives. They work well together.

Is vaginal oestrogen safe, including after breast cancer?

For most women, yes, and the safety conversation is genuinely different from the one about systemic HRT.

Because absorption is low and the action is local, vaginal oestrogen is generally regarded as suitable for long-term use, and low-dose vaginal preparations do not carry the same considerations as systemic therapy.

After breast cancer the situation requires individual specialist input rather than a blanket rule. Systemic HRT is generally avoided after breast cancer. Vaginal oestrogen for severe genitourinary symptoms is sometimes considered acceptable following discussion with the oncology or breast team, particularly where non-hormonal measures have not been enough. That decision belongs to the woman together with her oncology team and her gynaecologist, and it should never be made by an aesthetic clinic on the basis of an advertisement.

For women who cannot or prefer not to use any hormone, non-hormonal moisturisers used regularly, lubricants, pelvic floor physiotherapy and, where appropriate, other prescribed options can all help. There is always something to offer.

What is evidence-based and what is overhyped for intimate symptoms?

This is where I part company with a good deal of the aesthetic industry, and it is the section that took the longest to write, because I use a CO2 laser every week.

Energy-based devices, including fractional CO2 lasers, have been widely marketed for vaginal rejuvenation, with claims about dryness, laxity, urinary symptoms and sexual function. The evidence does not support those claims.

In 2021, JAMA published a double-blind, randomised, sham-controlled trial of fractional CO2 laser for postmenopausal vaginal symptoms. Eighty-five women were randomised, forty-three to laser and forty-two to sham, with three treatments four to eight weeks apart and twelve months of follow-up. At twelve months there was no significant difference between the laser and sham groups in symptom severity on either co-primary outcome measure, and no significant difference in quality of life scores, in the vaginal health index, or on histological comparison of tissue samples. Adverse events were similar in both groups. In other words, women improved in both arms, and the laser did not outperform a device that did nothing. The trial is cited as Li et al., JAMA 2021 (doi.org/10.1001/jama.2021.14892).

That trial did not appear in isolation. In July 2018 the United States Food and Drug Administration issued a safety communication warning patients and providers that the use of energy-based devices for vaginal rejuvenation, cosmetic vaginal procedures, or the treatment of symptoms related to menopause, urinary incontinence or sexual function may be associated with serious adverse events including vaginal burns, scarring, pain during intercourse and chronic pain, and that safety and effectiveness for these uses had not been established. The agency notified several manufacturers about their marketing. Subsequent sham-controlled trials, including in breast cancer survivors, have reached similar conclusions.

So my position is simple and I hold it publicly. I do not offer vaginal laser for rejuvenation, because I am not willing to charge a woman for something a sham device matched in a properly conducted trial.

What about the rest of menopause care?

Intimate symptoms are the part nobody asks about, but they are not the whole picture, and a proper assessment covers more.

Perimenopause, the transition of fluctuating hormones before the final period, often begins in the early forties and sometimes in the late thirties, and can last four to ten years. The average age of menopause in Ireland is around fifty-one. Because hormones fluctuate rather than decline smoothly, symptoms come and go, which is exactly why the diagnosis is missed and why blood tests are frequently unhelpful in perimenopause. It is usually a clinical picture built from your history and your pattern.

Beyond hot flushes, that picture commonly includes irregular cycles, broken sleep, mood change and anxiety, brain fog, low energy, joint aches, and changes in libido, skin and hair. Longer term, oestrogen loss has consequences for bone density and cardiovascular health that are worth discussing rather than discovering later.

Early menopause under forty-five and premature ovarian insufficiency under forty deserve particular attention, both because symptoms can be marked and because a longer period of oestrogen deficiency carries greater long-term implications. If your periods stopped early, please do not let anyone tell you to simply wait and see.

What does a menopause consultation at EC Clinic involve?

An unhurried conversation, a proper examination where indicated, and a plan you can actually follow.

In practice: a full history including symptoms, cycle pattern, medical and family history, medications and what you have already tried. Examination and ultrasound in the same visit where clinically indicated. A discussion of options, systemic and local, hormonal and non-hormonal, with the reasoning explained rather than asserted. A prescription where appropriate, along with a practical explanation of how to obtain it under the free HRT arrangement. And a written report on the same day, before you leave.

You can book directly. No GP referral is required in Ireland to see a private gynaecologist. We accept VHI, Laya Healthcare and Irish Life Health, and consultations are available in English, Spanish and Portuguese.

One last thing, and I mean it as more than a closing line. If you have been managing intimate dryness quietly for two years because it felt too small or too embarrassing to raise, it is not small. It is one of the most treatable things in all of menopause medicine, and the treatment for it is now, for most women, free at the pharmacy. Please come and ask.

Medically reviewed by Dr. Eliana Castañeda, Obstetrician-Gynaecologist and Aesthetic Specialist · 25 August 2026

— Dra. Eliana Castañeda
Ginecologista-obstetra e especialista em estética